{
    "clinical_study": {
        "@rank": "35069", 
        "arm_group": [
            {
                "arm_group_label": "ABT-199 Dose Escalation Cohorts", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ABT-199 Safety Expansion Cohort", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of this study are to assess the safety profile, characterize\n      pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and\n      recommended phase 2 dose (RPTD) of ABT-199 when administered in subjects with relapsed or\n      refractory multiple myeloma."
        }, 
        "brief_title": "A Phase I Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed/Refractory Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ECOG (Eastern Cooperative Oncology Group) performance score of 1 or 0.\n\n          -  Diagnosis of multiple myeloma previously treated with more than 1 prior line of\n             therapy, induction therapy followed by stem cell transplant and maintenance therapy\n             will be considered a single line of therapy (dose escalation only); or fewer than 4\n             separate lines of therapy (safety expansion only) including a proteasome inhibitor\n             and an IMiD or immunomodulatory agent (e.g., thalidomide, lenalidomide), induction\n             therapy followed by stem cell transplant and maintenance therapy will be considered a\n             single line of therapy.\n\n          -  Measurable disease at Screening: Serum monoclonal protein of at least 1.0 g/dL by\n             protein electrophoresis or at least 200 mg of monoclonal protein in the urine on\n             24-hr electrophoresis or serum immunoglobulin free light chain of at least 10 mg/dL\n             and abnormal serum immunoglobulin kappa to lambda free light chain ratio.\n\n          -  Subjects with a history of autologous or allogenic stem cell transplantation must\n             have adequate peripheral blood counts independent of any growth factor support, and\n             have recovered from any transplant related toxicity(s) and be at least 100 days\n             post-autologous transplant prior to first dose of study drug or at least 6 months\n             post-allogenic transplant prior to first dose of study drug and not have active\n             graft-versus-host disease (GVHD), i.e., requiring treatment.\n\n          -  Meet the following laboratory parameters, per the reference range: ANC of at least\n             1000/\u03bcL (Subjects with bone marrow that is heavily infiltrated with underlying\n             disease may use growth factor support to achieve ANC eligibility criteria, discussion\n             should occur between investigator and sponsor medical monitor regarding any subject's\n             use of growth factor to meet ANC criteria), AST and ALT not higher than 3 x ULN,\n             Calculated creatinine clearance of at least 30 mL/min using a modified\n             Cockcroft-Gault calculation (using Ideal Body Weight instead of Mass, subjects with\n             calculated creatinine clearance less than or equal to 50 mL/min should have medical\n             management discussed with sponsor medical monitor), platelet count of at least 30,000\n             mm\u00b3 (independent of transfusion for 2 weeks), hemoglobin of at least 9.0 g/dL, total\n             bilirubin not higher than 1.5 x ULN (subjects with Gilbert's Syndrome may have\n             bilirubin higher 1.5 x ULN with approval of sponsor medical monitor) and aPTT and PT\n             not higher than 1.2 x ULN.\n\n        Exclusion Criteria:\n\n          -  Exhibits evidence of other clinically significant uncontrolled condition(s),\n             including, but not limited to: uncontrolled systemic infection (viral, bacterial, or\n             fungal), diagnosis of fever and neutropenia within 1 week prior to first dose of\n             study drug.\n\n          -  Cardiovascular disability status of New York Heart Association Class greater than 2.\n             Class 2 is defined as cardiac disease in which patients are comfortable at rest but\n             ordinary physical activity results in fatigue, palpitations, dyspnea or anginal pain.\n\n          -  Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic,\n             immunologic, cardiovascular or hepatic disease, within the last 6 months that, in the\n             opinion of the investigator, would adversely affect his/her participation in the\n             study. For subjects who have required an intervention for any of the above diseases\n             within the past 6 months, a discussion with the investigator and the AbbVie medical\n             monitor must occur.\n\n          -  History of other active malignancies other than multiple myeloma within the past 3\n             years prior to study entry, with the following exceptions: adequately treated in situ\n             carcinoma of the cervix uteri, basal cell carcinoma of the skin or localized squamous\n             cell carcinoma of the skin, previous malignancy confined and surgically resected (or\n             treated with other modalities) with curative intent.\n\n          -  Tested positive for HIV.\n\n          -  Seropositive for hepatitis A, hepatitis B surface antigen, or hepatitis C virus\n             antibody or RNA.  Subjects with serologic evidence of prior vaccination to HBV may\n             participate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794520", 
            "org_study_id": "M13-367", 
            "secondary_id": "2012-000589-38"
        }, 
        "intervention": {
            "arm_group_label": [
                "ABT-199 Dose Escalation Cohorts", 
                "ABT-199 Safety Expansion Cohort"
            ], 
            "description": "ABT-199 dosed at cohort-defined dosing schedules and dose levels for Dose Escalation Cohorts, ABT-199 dosed at defined dose and schedule for Safety Expansion Cohort", 
            "intervention_name": "ABT-199", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "relapsed multiple myeloma", 
            "refractory multiple myeloma", 
            "relapsed/refractory multiple myeloma", 
            "multiple myeloma"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Site Reference ID/Investigator# 75808"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75808", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Site Reference ID/Investigator# 74993"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 74993", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Site Reference ID/Investigator# 74994"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 74994", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110-1093"
                    }, 
                    "name": "Site Reference ID/Investigator# 76094"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 76094", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "Site Reference ID/Investigator# 74995"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 74995", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes Cedex 1", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "Site Reference ID/Investigator# 75033"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 75033", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "lura.morris@abbvie.com", 
            "last_name": "Lura  Morris, BA", 
            "phone": "847-937-7534"
        }, 
        "overall_contact_backup": {
            "email": "kaffa.fakouhi@abbvie.com", 
            "last_name": "Kaffa  Fakouhi, BS", 
            "phone": "847-935-6462"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Sari  Enschede, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Collect all adverse events at each visit", 
                "measure": "Number and percentage of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From subject's first dose of ABT-199 until 30 days after the subject's last dose of ABT-199; up to 2 years after last subject's first dose"
            }, 
            {
                "description": "Blood pressure, heart rate and body temperature", 
                "measure": "Change in physical exam findings including vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From subject's baseline (prior to subject's first dose) up to 2 years following the last subject's first dose"
            }, 
            {
                "description": "ABT-199 will be dose escalated until the largest dose is reached that is felt to be safe based on adverse event reporting and dose-limiting toxicities information from all subjects", 
                "measure": "Determine dose and schedule of ABT-199", 
                "safety_issue": "Yes", 
                "time_frame": "Minimum first cycle of dosing (21 days) plus any lead-in period dosing (if used)"
            }, 
            {
                "description": "Hematology, chemistry, urinalysis, electrophoresis, immunofixation, viral serologies, free light chains", 
                "measure": "Change in clinical laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "From subject's baseline (prior to subject's first dose) up to 2 years following the last subject's first dose"
            }, 
            {
                "description": "Electrocardiogram and Multiple Gated Acquisition Scan and/or Echocardiogram", 
                "measure": "Change in cardiac assessment findings", 
                "safety_issue": "Yes", 
                "time_frame": "From subject's baseline (prior to subject's first dose) up to 2 years following the last subject's first dose"
            }, 
            {
                "description": "Blood samples for pharmacokinetic analysis of ABT-199 will be collected at designated timepoints", 
                "measure": "Determination of peak concentration (Cmax), trough concentration (Ctrough) and area under the concentration versus time curve (AUC) of ABT-199", 
                "safety_issue": "No", 
                "time_frame": "Dose Escalation Cohorts: once on Lead-in Days 1 and 8, Cycle 1 Day 1; 5 times on Cycle 2 Day 1; once on Cycle 2 Day 2 and Day 1 of Cycles 3, 5, 7 & 9.  Safety Expansion Cohort: once on Lead-in Days 1 and 8; once on Day 1 of Cycles 1, 2, 3, 5, 7 & 9."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794520"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of subjects with response using IMWG (International Myeloma Working Group) response criteria will be computed for all subjects with active disease at baseline (in the opinion of the investigator).", 
                "measure": "Calculation of Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Measured at Day 0, Cycle 3 Day 1, Cycle 5 Day 1 and Day 1 of every 4 cycles therafter (e.g., 9, 13, 17, etc.) up to 48 months"
            }, 
            {
                "description": "Number of days from the day of initial response is objectively documented to the day that disease progression is objectively documented.", 
                "measure": "Calculation of Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Measured at Day 0, Cycle 3 Day 1, Cycle 5 Day 1 and Day 1 of every 4 cycles therafter (e.g., 9, 13, 17, etc.) up to 48 months"
            }, 
            {
                "description": "Blood sample may be evaluated with goal of defining relationship between drug concentration and disease status", 
                "measure": "Exploratory pharmacogenetic study: Evaluate blood samples to define relationship between drug concentration and disease status", 
                "safety_issue": "No", 
                "time_frame": "Screening (prior to subject's first dose)"
            }, 
            {
                "description": "Blood samples may be evaluated with the goal of defining the relationship between drug concentration and disease status.", 
                "measure": "Change in Serum Markers and Plasma Markers Blood Samples", 
                "safety_issue": "No", 
                "time_frame": "From subject's baseline (prior to subject's first dose) up to 2 years following the last subject's first dose"
            }, 
            {
                "description": "Bone marrow aspirate and core biopsy samples may be evaluated with the goal of defining the relationship between drug concentration and disease status.", 
                "measure": "Change in bone marrow aspirate and core biopsy samples for Minimal Residual Disease (MRD), Cytogenetics/FISH, Bcl-2 Family Member Analysis, Bcl-2 Family Member Protein Analysis, in vitro Sensitivity, BH3 Profiling", 
                "safety_issue": "No", 
                "time_frame": "From subject's baseline (prior to subject's first dose) up to 2 years following the last subject's first dose"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}